Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Labaki

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Urologia|October 6, 2021
Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic reviewTalal Ziadeh, Roy Chebel, Chris Labaki, et al.
The Oncologist|May 31, 2022
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging LandscapeShuchi Gulati, Chris Labaki, Georgia Sofia Karachaliou, et al.
European Urology Oncology|February 2, 2022
Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial CarcinomaChris Labaki, Ziad Bakouny, Guru Sonpavde, et al.
Photodiagnosis and Photodynamic Therapy|February 2, 2021
The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic reviewElio Kechichian, Elie Helou, Julien Sarkis, et al.
Critical Reviews in Oncology/Hematology|April 16, 2020
Anti-neoplastic agents for patients on peritoneal dialysis: A systematic reviewChris Labaki, Elsa Rawadi, Roy Chebel, et al.
Cancer Treatment Reviews|May 15, 2022
Systematic review of the CUP trials characteristics and perspectives for next-generation studiesElie Rassy, Chris Labaki, Roy Chebel, et al.
World Journal of Urology|December 6, 2019
The use of mirabegron in neurogenic bladder: a systematic reviewElie El Helou, Chris Labaki, Roy Chebel, et al.
Hematology/Oncology Clinics of North America|June 30, 2023
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 AxesEddy Saad, Renée Maria Saliby, Chris Labaki, et al.
Hematology/Oncology Clinics of North America|June 29, 2023
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR InhibitionRenée Maria Saliby, Eddy Saad, Chris Labaki, et al.
Cancer Cell|July 15, 2021
Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemicChris Labaki, Ziad Bakouny, Andrew Schmidt, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Urologia|October 6, 2021
Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic reviewTalal Ziadeh, Roy Chebel, Chris Labaki, et al.
The Oncologist|May 31, 2022
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging LandscapeShuchi Gulati, Chris Labaki, Georgia Sofia Karachaliou, et al.
European Urology Oncology|February 2, 2022
Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial CarcinomaChris Labaki, Ziad Bakouny, Guru Sonpavde, et al.
Photodiagnosis and Photodynamic Therapy|February 2, 2021
The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic reviewElio Kechichian, Elie Helou, Julien Sarkis, et al.
Critical Reviews in Oncology/Hematology|April 16, 2020
Anti-neoplastic agents for patients on peritoneal dialysis: A systematic reviewChris Labaki, Elsa Rawadi, Roy Chebel, et al.
Cancer Treatment Reviews|May 15, 2022
Systematic review of the CUP trials characteristics and perspectives for next-generation studiesElie Rassy, Chris Labaki, Roy Chebel, et al.
World Journal of Urology|December 6, 2019
The use of mirabegron in neurogenic bladder: a systematic reviewElie El Helou, Chris Labaki, Roy Chebel, et al.
Hematology/Oncology Clinics of North America|June 30, 2023
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 AxesEddy Saad, Renée Maria Saliby, Chris Labaki, et al.
Hematology/Oncology Clinics of North America|June 29, 2023
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR InhibitionRenée Maria Saliby, Eddy Saad, Chris Labaki, et al.
Cancer Cell|July 15, 2021
Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemicChris Labaki, Ziad Bakouny, Andrew Schmidt, et al.
Pageof 8